These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 32190806)

  • 1. Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity.
    Iacobellis G; Villasante Fricke AC
    J Endocr Soc; 2020 Apr; 4(4):bvz042. PubMed ID: 32190806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
    Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
    Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study).
    Nomoto H; Oba-Yamamoto C; Takahashi Y; Takeuchi J; Nagai S; Yokoyama H; Taneda S; Kurihara Y; Aoki S; Kameda H; Cho KY; Nakamura A; Atsumi T; Miyoshi H
    Diabetes Ther; 2021 Mar; 12(3):955-964. PubMed ID: 33491111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults.
    Liebisch-Rey H; Suarez-Chacon AM; Fuentes YV; Blanco J; Kock J; Lechtig-Wassermann S; Bustos RH
    F1000Res; 2023; 12():914. PubMed ID: 38125558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
    Gæde P; Johansen P; Tikkanen CK; Pollock RF; Hunt B; Malkin SJP
    Diabetes Ther; 2019 Aug; 10(4):1297-1317. PubMed ID: 31098942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study.
    Jain AB; Kanters S; Khurana R; Kissock J; Severin N; Stafford SG
    Diabetes Ther; 2021 Feb; 12(2):527-536. PubMed ID: 33367981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.
    Viljoen A; Hoxer CS; Johansen P; Malkin S; Hunt B; Bain SC
    Diabetes Obes Metab; 2019 Mar; 21(3):611-621. PubMed ID: 30362224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes.
    Webb N; Orme M; Witkowski M; Nakanishi R; Langer J
    Diabetes Ther; 2018 Jun; 9(3):973-986. PubMed ID: 29574633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting.
    Uzoigwe C; Liang Y; Whitmire S; Paprocki Y
    Diabetes Ther; 2021 May; 12(5):1475-1489. PubMed ID: 33837922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes in the United Kingdom and Germany: A Retrospective Cohort Study.
    Barrett A; Debackere N; Ribeiro A; Keapoletswe K; Zingel R; Coles B
    Adv Ther; 2023 Aug; 40(8):3446-3464. PubMed ID: 37286889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
    Pratley RE; Aroda VR; Lingvay I; Lüdemann J; Andreassen C; Navarria A; Viljoen A;
    Lancet Diabetes Endocrinol; 2018 Apr; 6(4):275-286. PubMed ID: 29397376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
    Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
    Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network.
    García-Vega D; Sánchez-López D; Rodríguez-Carnero G; Villar-Taibo R; Viñuela JE; Lestegás-Soto A; Seoane-Blanco A; Moure-González M; Bravo SB; Fernández ÁL; González-Juanatey JR; Eiras S
    Cardiovasc Diabetol; 2024 Jan; 23(1):1. PubMed ID: 38172989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.
    Hunt B; Malkin SJP; Moes RGJ; Huisman EL; Vandebrouck T; Wolffenbuttel BHR
    BMJ Open Diabetes Res Care; 2019; 7(1):e000705. PubMed ID: 31641522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis.
    Zhuo C; Lin C; Zhou C; Gao X; Shao H; Fang T; Tian H; Ding L; Liu M
    Front Pharmacol; 2021; 12():759262. PubMed ID: 35002700
    [No Abstract]   [Full Text] [Related]  

  • 16. Semaglutide Versus Other Glucagon-Like Peptide-1 Agonists for Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis.
    Wen J; Nadora D; Bernstein E; How-Volkman C; Truong A; Akhtar M; Prakash NA; Puglisi J; Frezza E
    Cureus; 2024 Sep; 16(9):e69008. PubMed ID: 39385875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.
    Martín V; Vidal J; Malkin SJP; Hallén N; Hunt B
    Adv Ther; 2020 Oct; 37(10):4427-4445. PubMed ID: 32862365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide causes large and rapid epicardial fat reduction.
    Iacobellis G; Mohseni M; Bianco SD; Banga PK
    Obesity (Silver Spring); 2017 Feb; 25(2):311-316. PubMed ID: 28124506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.